News by Subject Policy & Ethics

A new perspective piece highlights the regulatory, ethical and scientific issues associated with US 'stem cell clinics' registering pay-to-participate stem cells studies on the NIH registry and database, ClinicalTrials.gov.

In new research, led by Brigham and Women's Hospital, researchers tested a structured and technology-centered program that was focused on team communication and patient engagement. They found that this approach was associated with a lower rate of adverse events and improved patient satisfaction.

In light of the British Lion's rugby success, Newcastle University experts warn steps need to be taken to ensure children's safety when they play the sport.

What exactly are the laws governing patient recordings? In an article recently published in the Journal of American Medicine (JAMA), investigators on The Dartmouth Institute for Health Policy and Clinical Practice's Open Recordings Project explain the often-confusing laws around recordings clinical visits.

Using texts, emails, Skype and other digital communication methods can improve the health care experience of younger patients. That is the conclusion of new research, led by the University of Warwick and King's College London, which examined case studies from 20 NHS specialist clinical teams from across England and Wales.

Countries should unite to tackle unscrupulous advertising of unproven therapies involving stem cells, experts say. An international group of leading experts has called for tighter regulation of so-called stem cell tourism. This involves patients traveling to other countries, where medical regulations are less strict, for treatment with potentially unsafe therapies. Researchers say the practice risks undermining the development of rigorously tested, validated therapies and puts lives at risk.

State spending cuts during economic downturns fall more heavily on children than the elderly, according to new research by experts at Rice University. Their findings are published in the National Tax Journal and analyze implications for policymakers.

Cancer scientists overestimate the extent to which high-profile preclinical studies can be successfully replicated, new research from McGill University suggests.